
BioPorto Investor Relations Material
Latest events

Status Update
BioPorto
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from BioPorto
Access all reports
BioPorto A/S is a global biotech company that specializes in the development and manufacturing of in-vitro diagnostic tests and antibodies for both research and clinical applications. The company's diagnostics products are primarily based on a patented proprietary technology platform called MoAb®. The Company's products are used in research, including preclinical studies and clinical trials, as well as in diagnosis procedures to detect infectious diseases, cancer, autoimmune disorders and other diseases. BioPorto A/S is based in Hellerup, Denmark.
Key slides for BioPorto


Status Update
BioPorto


Q2 2025
BioPorto
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
BIOPOR
Country
🇩🇰 Denmark